➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Harvard Business School
Dow
AstraZeneca
Medtronic

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,532,994

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,532,994
Title:Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
Abstract: The present invention discloses agents and methods for inducing osteoblastic cellular differentiation, as well as the use of such agents and methods to treat patients to maintain bone mass, enhance bone formation and/or bone repair. Exemplary agents include oxysterols, alone or in combination with particular oxysterols, or other agents, such as bone morphogenic proteins, known to assist in bone formation. The invention further includes medicaments including oxysterols for the treatment of bone disorders and implants to facilitate bone repair.
Inventor(s): Parhami; Farhad (Los Angeles, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
Application Number:10/569,994
Patent Claims:1. A method of inducing osteoblastic differentiation and inhibiting adipocyte differentiation of mammalian mesenchymal stem cells comprising administering a combination of 20S-hydroxycholesterol and 22S-hydroxycholesterol and at least one bone morphogenic protein to contact the mammalian mesenchymal stem cells and induce osteoblastic differentiation and inhibit adipocyte differentiation of the mammalian mesenchymal stem cells, wherein the at least one bone morphogenic protein is selected from the group consisting of BMP7, BMP14, and combinations.

2. The method of claim 1, further comprising treating the mammalian mesenchymal stem cells with a cytochrome P450 inhibitor.

3. The method of claim 1, further comprising treating the mammalian mesenchymal cells with at least one secondary agent selected from the group consisting of parathyroid hormone, sodium fluoride, insulin-like growth factor I, insulin-like growth factor II or transforming growth factor beta, bisphosphonates, estrogen receptor modulators, calcitonin, vitamin D, and calcium.

4. The method of claim 1, wherein the mammalian mesenchymal stem cells are of a patient.

5. The method of claim 1, wherein the mammalian mesenchymal stem cells are in a patient affected by bone loss, and wherein inducing osteoblastic differentiation and inhibiting adipocyte differentiation of the mammalian mesenchymal stem cells results in increased bone mass and enhanced bone repair in the patient.

6. The method of claim 1, wherein the mammalian mesenchymal stem cells are in a patient exhibiting clinical symptoms of osteoporosis, and wherein inducing osteoblastic differentiation and inhibiting adipocyte differentiation of the mammalian mesenchymal stem cells ameliorates the symptoms of osteoporosis in the patient.

7. The method of claim 1, wherein the mammalian mesenchymal stem cells are in a patient in need of bone formation, and wherein inducing osteoblastic differentiation and inhibiting adipocyte differentiation of the mammalian mesenchymal stem cells induces bone formation in the patient.

8. The method of claim 7, wherein the bone formation is endochondral or intramembraneous bone formation.

9. The method of claim 1, wherein the mammalian mesenchymal stem cells are ex vivo, and wherein the method further comprises administering the osteoblastic differentiated cells to a patient in need of bone formation by applying the osteoblastic differentiated cells to a selected site in the patient where bone formation is desired.

10. The method of claim 1, wherein the at least one bone morphogenic protein is BMP7.

11. The method of claim 1, wherein the at least one bone morphogenic protein is BMP14.

12. The method of claim 1, wherein the at least one bone morphogenic protein is the combination of BMP7 and BMP14.

13. A method of stimulating mammalian cells to express a level of a biological marker of osteoblastic differentiation which is greater than the level of the biological marker in untreated mammalian cells, comprising administering a combination of 20S-hydroxycholesterol and 22S-hydroxycholesterol and at least one bone morphogenic protein to the mammalian cells in an amount sufficient to induce the osteoblastic differentiation of the mammalian cells, wherein the at least one bone morphogenic protein is selected from the group consisting of BMP7, BMP14, and combinations, and wherein the mammalian cells are selected from the group consisting of mammalian mesenchymal stem cells, mammalian preosteoblast cells, and mammalian pluripotent embryonic fibroblast cells.

14. The method of claim 13, wherein the biological marker of osteogenic differentiation is at least one of calcium incorporation, mineralization, expression of osteocalcin mRNA, activation of the ERK pathway, and expression of Cbfa1.

15. The method of claim 13, further comprising treating the mammalian cells with a cytochrome P450 inhibitor.

16. The method of claim 13, further comprising treating the mammalian cells with at least one secondary agent selected from the group consisting of parathyroid hormone, sodium fluoride, insulin-like growth factor I, insulin-like growth factor II or transforming growth factor beta, bisphosphonates, estrogen receptor modulators, calcitonin, vitamin D, and calcium.

17. The method of claim 13, wherein the mammalian cells are mammalian mesenchymal stem cells.

18. The method of claim 13, wherein the at least one bone morphogenic protein is BMP7.

19. The method of claim 13, wherein the at least one bone morphogenic protein is BMP14.

20. The method of claim 13, wherein the at least one bone morphogenic protein is the combination of BMP7 and BMP14.

21. A method for treating a patient to induce bone formation comprising: harvesting mammalian mesenchymal stem cells; treating the mammalian mesenchymal cells by the method of claim 1; and administering the differentiated cells to the patient to induce bone formation.

22. An implant for use in the human body for bone formation comprising a substrate having a surface, wherein at least the surface comprises a combination of 20S-hydroxycholesterol and 22S-hydroxycholesterol and at least one bone morphogenic protein, wherein after implantation the implant administers the combination of 20S-hydroxycholesterol and 22S-hydroxycholesterol and at least one bone morphogenic protein in an amount sufficient to induce osteoblastic differentiation and inhibit adipocyte differentiation of mammalian mesenchymal stem cells for bone formation in bone tissue proximate to the implant, and wherein the at least one bone morphogenic protein is selected from the group consisting of BMP7, BMP14, and combinations.

23. The implant of claim 22, wherein the substrate is formed into the shape of a pin, screw, plate, or prosthetic joint.

24. The implant of claim 22, wherein the at least one bone morphogenic protein is BMP7.

25. The implant of claim 22, wherein the at least one bone morphogenic protein is BMP14.

26. The implant of claim 22, wherein the at least one bone morphogenic protein is the combination of BMP7 and BMP14.

27. A medicament for inducing osteoblastic differentiation and inhibiting adipocyte differentiation of mammalian mesenchymal stem cells, comprising a therapeutically effective dosage of a combination of 20S-hydroxycholesterol and 22S-hydroxycholesterol and at least one bone morphogenic protein, wherein the at least one bone morphogenic protein is selected from the group consisting of BMP7, BMP14, and combinations and wherein upon administration to a patient the medicament induces osteoblastic differentiation and inhibits adipocyte differentiation of mammalian mesenchymal stem cells.

28. The medicament of claim 27, wherein the at least one bone morphogenic protein is BMP7.

29. The medicament of claim 27, wherein the at least one bone morphogenic protein is BMP14.

30. The medicament of claim 27, wherein the at least one bone morphogenic protein is the combination of BMP7 and BMP14.

Summary for Patent:   Start Trial

PCT Information
PCT FiledAugust 30, 2004PCT Application Number:PCT/US2004/028162
PCT Publication Date:March 10, 2005PCT Publication Number:WO2005/020928

Details for Patent 9,532,994

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) 2023-08-29 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) 2023-08-29 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) 2023-08-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Moodys
Express Scripts
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.